On December 2, 2024, the United States Securities and Exchange Commission (SEC) declared the effectiveness of BioVie's S-1 registration statement. This marks a significant step for BioVie, as the S-1 form is typically used for initial public offerings (IPOs) or other securities offerings.The effectiveness of the S-1 registration allows BioVie to proceed with its planned securities offering, which could potentially raise capital for the company's operations and growth initiatives. Investors should monitor BioVie's subsequent announcements for details on the offering size, pricing, and timeline.This development is crucial for BioVie's strategic financial planning, as it opens up opportunities for market expansion and increased investor engagement.

On December 2, 2024, the United States Securities and Exchange Commission (SEC) declared the effectiveness of BioVie's S-1 registration statement. This marks a significant step for BioVie, as the S-1 form is typically used for initial public offerings (IPOs) or other securities offerings.The effectiveness of the S-1 registration allows BioVie to proceed with its planned securities offering, which could potentially raise capital for the company's operations and growth initiatives. Investors should monitor BioVie's subsequent announcements for details on the offering size, pricing, and timeline.This development is crucial for BioVie's strategic financial planning, as it opens up opportunities for market expansion and increased investor engagement.